Edge Capital Group LLC acquired a new position in Baxter International Inc (NYSE:BAX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,853 shares of the medical instruments supplier’s stock, valued at approximately $254,000.
A number of other institutional investors have also bought and sold shares of BAX. Gantzert Investment Co. LLC ADV acquired a new position in Baxter International in the fourth quarter worth $25,000. Parisi Gray Wealth Management acquired a new position in Baxter International in the fourth quarter worth $26,000. Baldwin Brothers Inc. MA lifted its stake in shares of Baxter International by 904.0% during the fourth quarter. Baldwin Brothers Inc. MA now owns 502 shares of the medical instruments supplier’s stock valued at $33,000 after acquiring an additional 452 shares during the period. We Are One Seven LLC acquired a new position in shares of Baxter International during the fourth quarter valued at $34,000. Finally, Financial Gravity Companies Inc. acquired a new position in shares of Baxter International during the fourth quarter valued at $45,000. 84.25% of the stock is currently owned by institutional investors.
Several equities analysts have recently issued reports on the company. Zacks Investment Research raised Baxter International from a “hold” rating to a “buy” rating and set a $86.00 price target on the stock in a research note on Tuesday. Morgan Stanley upped their price target on Baxter International from $80.00 to $83.00 and gave the company an “overweight” rating in a research note on Tuesday, March 5th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $80.00 price target on shares of Baxter International in a research note on Friday, February 1st. Barclays raised Baxter International from an “underweight” rating to an “equal weight” rating and upped their price target for the company from $67.00 to $72.00 in a research note on Friday, February 1st. Finally, Wells Fargo & Co upped their price target on Baxter International from $72.00 to $76.00 and gave the company an “outperform” rating in a research note on Tuesday, December 4th. Three analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $77.31.
Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, January 31st. The medical instruments supplier reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The business had revenue of $2.84 billion during the quarter, compared to the consensus estimate of $2.80 billion. Baxter International had a return on equity of 19.10% and a net margin of 14.60%. On average, equities research analysts predict that Baxter International Inc will post 3.27 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 1st. Investors of record on Friday, March 1st will be issued a $0.19 dividend. The ex-dividend date is Thursday, February 28th. This represents a $0.76 dividend on an annualized basis and a yield of 0.97%. Baxter International’s dividend payout ratio is presently 24.92%.
In related news, SVP Giuseppe Accogli sold 38,297 shares of the company’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $76.78, for a total value of $2,940,443.66. Following the completion of the sale, the senior vice president now owns 70,001 shares in the company, valued at $5,374,676.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John D. Forsyth sold 1,500 shares of the company’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $75.92, for a total value of $113,880.00. Following the completion of the sale, the director now owns 31,703 shares of the company’s stock, valued at approximately $2,406,891.76. The disclosure for this sale can be found here. Insiders sold 82,896 shares of company stock valued at $6,157,104 in the last quarter. 0.07% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Edge Capital Group LLC Acquires New Position in Baxter International Inc (BAX)” was first published by WKRB News and is owned by of WKRB News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.wkrb13.com/2019/03/22/edge-capital-group-llc-acquires-new-position-in-baxter-international-inc-bax.html.
Baxter International Company Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Further Reading: Why is a lock-up period needed for an IPO?
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.